Rate My Professor Mageswary Sivalingam

Dr. Mageswary Sivalingam is a Lecturer in the Jeffrey Cheah School of Medicine and Health Sciences at Monash University Malaysia. She joined the institution as an Assistant Lecturer in June 2019, shortly after completing her PhD in Neuroscience from Monash University Malaysia on 19 April 2019. Her doctoral research, titled "Habenula Kisspeptin Suppresses Morphine Mediated Fear Memory Consolidation," employed zebrafish models to explore the mechanisms by which habenula kisspeptin mitigates morphine-mediated impairment of fear memory consolidation. Prior to her PhD, she conducted various research projects in neuroscience using fish as models and morphological techniques. She holds a Master of Science in Molecular Biology from Universiti Kebangsaan Malaysia, awarded on 1 October 2012, with a thesis entitled "Genotype phenotype correlation in beta thalassaemia," and a Bachelor of Science in Microbiology from Universiti Sains Malaysia, awarded on 1 October 2005. Her academic training spans neuroscience, molecular biology, and molecular morphology.

Dr. Sivalingam's research interests center on negative emotions and related psychiatric disorders, such as post-traumatic stress disorder (PTSD), depression, and associated neurodegenerative diseases, along with mental health disorders, neuroinflammation, and molecular biology. Key publications include "Chronic unpredictable stress (CUS) reduced phoenixin expression, induced abnormal sperm and testis morphology in male rats" (Neuropeptides, October 2024), "Regulation of EMT Markers, Extracellular Matrix, and Associated Signalling Pathways by Long Non-Coding RNAs in Glioblastoma Mesenchymal Transition: A Scoping Review" (Biology, June 2023), "Conserved functions of hypothalamic kisspeptin in vertebrates" (General and Comparative Endocrinology, February 2022), and "Hypothalamic kisspeptin and kisspeptin receptors: Species variation in reproduction and reproductive behaviours" (Frontiers in Neuroendocrinology, January 2022). She has received a Prize in 2021 for "A novel anti-NRP2 monoclonal antibody-based therapeutics against Chikungunya virus (CHIKV)" and an Other Distinction in 2020 for "Cross-talks between Inflammation and the gut microbiome: Implications on mental illness with the alteration of the metabolic system." Dr. Sivalingam is currently accepting PhD students, contributes to SDG 3 Good Health and Well-being, and is a member of the programme committee for "Co-design for Equitable Research in Women’s Health" scheduled for 15 July 2025.